Non-Invasive Neurostimulation Is Fastest Growing Segment Fueling The Growth Of Cluster Headache Market
Cluster Headache Market |
The global Cluster Headache Market is estimated to be valued at US$ 402.12 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Cluster headaches (CH) are one of the most painful conditions known and are characterized by recurrent episodes of severe, rapid-onset pain on one side of the head. Non-invasive neurostimulation devices offer quick, targeted pain relief without the need for medication overuse or potential side effects.
Market key trends:
Increasing demand for non-invasive treatment options is one of the key trends in the cluster headache market. Non-invasive neurostimulation devices provide an alternative to medications for preventing CH attacks with minimal side effects. Devices like gammaCore and Cefaly utilize vagus and trigeminal nerve stimulation respectively to stop pain signals from reaching the brain. Their ease of use and quick relief are driving greater adoption among CH patients.
Segment Analysis
The global cluster headache market can be segmented into drug type and distribution channel. Based on drug type, the triptans segment dominated the market in 2021. Triptans segment held the largest share of cluster headache owing to their effectiveness in acute treatment of headaches compared to other treatments. Triptans work by constricting dilated blood vessels in the brain to relieve cluster headaches and pain. Based on distribution channel, the hospital pharmacies segment dominated the market in 2021. The hospital pharmacies segment accounted for highest share owing to increasing healthcare expenditure and focus on management of complex headache cases in hospitals.
Key Takeaways
The Global Cluster Headache Market Size is expected to witness high growth, exhibiting a CAGR of 6.4% over the forecast period from 2023 to 2030, due to increasing prevalence of headache disorders.
Regional analysis: North America dominated the global cluster headache market in 2021. This is attributable to increasing healthcare expenditure, rising awareness about headache disorders and presence of key players in the region. Asia Pacific is expected to witness rapid growth during the forecast period owing to expanding healthcare infrastructure, high unmet needs, and growing medical tourism in emerging nations such as China and India.
Key players: Key players operating in the cluster headache market are Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.
Explorer more information on this topic, Please visit -
Comments
Post a Comment